NASDAQ · TLPH
Healthcare · Drug Manufacturers - Specialty & Generic
$1.05
Down-$0.06 (-5.41%)
Updated Oct 8, 2026, 4:10 AM
SID Score
4.1/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · TLPH
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 7, 2026
TLPH closed at $1.05 after 21 trading sessions, down 13.93% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 7, 2026 | $1.10 | $1.11 | $1.05 | $1.05 | 270.22K |
| Oct 6, 2026 | $1.16 | $1.18 | $1.10 | $1.11 | 115.79K |
| Oct 5, 2026 | $1.15 | $1.19 | $1.13 | $1.16 | 587.12K |
| Oct 2, 2026 | $1.11 | $1.14 | $1.09 | $1.13 | 345.05K |
| Oct 1, 2026 | $1.17 | $1.17 | $1.12 | $1.12 | 106.4K |
| Sep 30, 2026 | $1.17 | $1.1876 | $1.16 | $1.16 | 56.1K |
| Sep 29, 2026 | $1.20 | $1.2099 | $1.17 | $1.17 | 66.9K |
| Sep 28, 2026 | $1.18 | $1.21 | $1.16 | $1.19 | 188.29K |
| Sep 25, 2026 | $1.17 | $1.1899 | $1.17 | $1.18 | 131.74K |
| Sep 24, 2026 | $1.17 | $1.18 | $1.15 | $1.17 | 145.46K |
| Sep 23, 2026 | $1.16 | $1.175 | $1.15 | $1.16 | 81.35K |
| Sep 22, 2026 | $1.18 | $1.18 | $1.15 | $1.17 | 44.4K |
| Sep 21, 2026 | $1.16 | $1.17 | $1.15 | $1.17 | 136.56K |
| Sep 18, 2026 | $1.17 | $1.1799 | $1.16 | $1.16 | 79.5K |
| Sep 17, 2026 | $1.21 | $1.21 | $1.16 | $1.17 | 110.98K |
| Sep 16, 2026 | $1.19 | $1.20 | $1.16 | $1.19 | 228.06K |
| Sep 15, 2026 | $1.24 | $1.24 | $1.18 | $1.19 | 164.59K |
| Sep 14, 2026 | $1.26 | $1.26 | $1.2088 | $1.24 | 25.67K |
| Sep 11, 2026 | $1.24 | $1.26 | $1.23 | $1.24 | 151.34K |
| Sep 10, 2026 | $1.2001 | $1.245 | $1.19 | $1.24 | 217.15K |
| Sep 9, 2026 | $1.20 | $1.23 | $1.19 | $1.22 | 62.91K |
The latest Smart Investors Daily articles mentioning TLPH.
Company
Market Activity
Research & News
TLPH research
Company profile and research snapshot.
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Apr 30, 2026 | WestPark Capital | Buy | — |
| Apr 1, 2025 | HC Wainwright & Co. | Buy | — |
| Jan 21, 2025 | HC Wainwright & Co. | Buy | — |
| Aug 16, 2024 | HC Wainwright & Co. | Buy | — |
| May 15, 2024 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
Yahoo · Sep 21, 2026
Talphera (TLPH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Yahoo · Sep 3, 2026
Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that Company management will be presenting at the H.C. Wainwright 28th Annual Global Investment Conference.
SeekingAlpha · Aug 13, 2026
Talphera, Inc. (TLPH) Q2 2026 Earnings Call August 12, 2026 4:30 PM EDTCompany ParticipantsRaffi Asadorian - Chief Financial OfficerVincent Angotti - CEO...
Benzinga · Aug 12, 2026
Talphera (NASDAQ:TLPH) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.07) by 14.29 percent. This is a 40 percent increase over losses of $(0.10) per share from the same
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning TLPH.
